Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T16:43:20.072Z.
Calculation as of: 2026-10-06T16:43:20.072Z.
Quote observation: 2026-10-06T16:40:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d8f500f051b8c2f6d9df2326c38ce0bcf8edb39987555b97daf7c0f1a95d0fd4
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
LENZ Therapeutics, Inc.
Market Cap
$118.05M
EBITDA Yield
N/A
| NAME | MARKET CAP | EBITDA YIELD |
|---|---|---|
| LENZ Therapeutics, Inc. (LENZ) | $118.05M | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $117.05M | N/A |
| Caribou Biosciences, Inc. (CRBU)vs › | $117.03M | N/A |
| Genelux Corporation (GNLX)vs › | $115.69M | N/A |
| Lucid Diagnostics Inc. (LUCD)vs › | $115.51M | N/A |
| Seer, Inc. (SEER)vs › | $121.31M | N/A |
| Cibus, Inc. (CBUS)vs › | $121.75M | N/A |
| TuHURA Biosciences, Inc. (HURA)vs › | $121.95M | N/A |
| enGene Holdings Inc. (ENGN)vs › | $122.26M | N/A |
| Foghorn Therapeutics Inc. (FHTX)vs › | $113.32M | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
